ContraFect_LOGO_Web.jpg
ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium
June 03, 2019 07:00 ET | ContraFect Corporation
YONKERS, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect_LOGO_Web.jpg
ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal
May 31, 2019 07:00 ET | ContraFect Corporation
YONKERS, N.Y., May 31, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect_LOGO_Web.jpg
ContraFect Reports First Quarter 2019 Financial Results and Provides Business Update
May 10, 2019 07:00 ET | ContraFect Corporation
YONKERS, N.Y., May 10, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents,...
ContraFect_LOGO_Web.jpg
ContraFect to Present at the Bacteriophage Therapy Summit
March 21, 2019 07:00 ET | ContraFect Corporation
YONKERS, N.Y., March 21, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated...
ContraFect_LOGO_Web.jpg
ContraFect Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
March 14, 2019 07:00 ET | ContraFect Corporation
YONKERS, N.Y., March 14, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated...
ContraFect_LOGO_Web.jpg
ContraFect to Present at the Oppenheimer 29th Annual Healthcare Conference
March 13, 2019 07:00 ET | ContraFect Corporation
YONKERS, New York, March 13, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated...
ContraFect_LOGO_Web.jpg
ContraFect Announces $6.94 Million in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-negative ESKAPE Pathogens
March 04, 2019 07:00 ET | ContraFect Corporation
YONKERS, N.Y., March 04, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect_LOGO_Web.jpg
ContraFect Announces Oral Presentation at the 2019 Gordon Research Conference on Mechanisms and Application: Realizing the Potential of Antimicrobial Host Defense Peptides for Human and Veterinary Medicine
February 13, 2019 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Feb. 13, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect_LOGO_Web.jpg
ContraFect Announces Additional $2.3 Million in Funding from CARB-X to Support Gram-Negative Lysin Program
January 17, 2019 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect_LOGO_Web.jpg
ContraFect to Present at Biotech Showcase 2019
December 20, 2018 17:00 ET | ContraFect Corporation
YONKERS, N.Y., Dec. 20, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...